The following technology is the basis for conducting the EpiRespond®-Test

In the last decade, rapid progress in molecular biological platform technologies has demonstrated that not only DNA-mutations in genes and differential mRNA-expression of genes are associated with malignancy but also epigenetic changes, yielding stable marks on top of genetic information in tumor tissues, are of great importance in the development, progression, and spread of cancer, including breast cancer. By comparison of fluorescence signal development during PCR, the methylation ratio can be calculated by a modified 2exp-DDCT method, resulting in a percent methylation ratio (PMR) for each sample individually

(For data analysis see Harbeck, N., I. Nimmrich, et al. (2008). „Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.“ J Clin Oncol 26(31): 5036-42).

© 2017 Therawis GmbH - All Rights Reserved